00574.HK
Pa Shun International Holdings Limited
HKSE · Healthcare · Medical - Pharmaceuticals · HK
HKD 0.02
−10.00%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 173.4M | 86.8M | 86.6M | 129.4M | 71.8M |
| Cost of Revenue | 144.3M | 74.8M | 69.5M | 100.0M | 58.5M |
| Gross Profit | 29.1M | 12.0M | 17.1M | 29.4M | 13.3M |
| Operating Expenses | |||||
| R&D Expense | — | — | — | — | — |
| SG&A Expense | 41.2M | 19.2M | 22.0M | 30.8M | 18.9M |
| General & Admin Expense | 28.6M | 14.6M | 14.0M | 23.6M | 12.8M |
| Selling & Marketing Expense | 12.6M | 4.6M | 8.0M | 7.2M | 6.0M |
| Other Expenses | (14.0M) | (11.6M) | 1.1M | (512.0K) | (512.0K) |
| Total Operating Expenses | 27.2M | 7.6M | 23.1M | 30.3M | 18.4M |
| Cost and Expenses | 171.5M | 82.4M | 92.6M | 130.3M | 76.9M |
| Operating Income (EBIT) | 1.9M | 4.4M | (6.1M) | (901.0K) | (5.9M) |
| Non-Operating | |||||
| Interest Income | 15.2K | 2.9K | 11.0K | 3.0K | 7.0K |
| Interest Expense | 21.4M | 14.6M | 14.8M | 12.9M | 10.5M |
| Net Interest Income | (21.4M) | (14.6M) | (14.8M) | (12.9M) | (10.5M) |
| Other Non-Op Income/Expense | (32.6M) | (20.1M) | (8.9M) | 4.3M | (37.2M) |
| Non-Operating Income (excl Interest) | (898.0K) | — | (5.9M) | (17.2M) | 27.6M |
| EBT (Pre-Tax Income) | (30.7M) | (15.7M) | (15.0M) | 3.4M | (43.2M) |
| Income Tax Expense | 494.0K | 187.0K | 307.0K | 1.1M | 220.0K |
| Bottom Line | |||||
| Net Income | (31.2M) | (15.9M) | (15.3M) | 2.4M | (43.4M) |
| Earnings from Cont. Ops | (31.2M) | (15.9M) | (15.3M) | 2.4M | (43.4M) |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | (31.2M) | (15.9M) | (15.3M) | 2.4M | (43.4M) |
| Per Share | |||||
| Basic EPS | (HK$0.02) | (HK$0.01) | (HK$0.01) | HK$0.00 | (HK$0.03) |
| Diluted EPS | (HK$0.02) | (HK$0.01) | (HK$0.01) | HK$0.00 | (HK$0.03) |
| Revenue Per Share | HK$0.12 | HK$0.06 | HK$0.06 | HK$0.09 | HK$0.05 |
| Shares | |||||
| Basic Shares Outstanding | 1.5B | 1.5B | 1.5B | 1.5B | 1.5B |
| Diluted Shares Outstanding | 1.5B | 1.5B | 1.5B | 1.5B | 1.5B |
| Profitability Metrics | |||||
| EBITDA | 8.8M | 7.5M | 2.9M | 19.6M | (3.3M) |
| D&A | 6.0M | 3.1M | 3.1M | 3.3M | 2.7M |
| EBIT | 2.8M | 4.4M | (206.0K) | 16.3M | (5.9M) |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Dec 1, 2025